MAP2K7 and keratoacanthoma: The most common side effect of trametinib (MEK inhibitor) in human patients is skin rush, and common toxicity associated with vemurafenib (BRAF inhibitor) is cutaneous abnormalities such as keratoacanthoma and squamous cell carcinoma by the mechanism of paradoxical MAPK pathway activation49.